Danielle Antelfi
UBS, Analyst
Replay available
Boston Scientific Corporation (BSX) Q3 2025 Earnings Call
Boston Scientific Corporation (NYSE: BSX) Q3 2025 earnings conference call, held 2025-10-22. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Chris Pasquale
Nefron Research, Analyst
Travis Steed
Bank of America, Analyst
Michael Pollard
Wolf Research, Analyst
David Roman
Goldman Sachs, Analyst
Vijay Kumar
Evercore ISI, Analyst
Pito Chikring
Deutsche Bank, Analyst
Rick Wise
Stifel, Analyst
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Boston Scientific Corporation.
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:03.855 Thanks, Mike. Thanks, Larry. Thinking 00:00:03.855 -- 00:00:09.761 about 20% growth over a sustained number of years of the LRP as conservative 00:00:09.761 -- 00:00:14.866 just says something about just how impactful Watchman has been as a therapy 00:00:14.866 -- 00:00:18.289 and I think will continue to be. As 00:00:18.289 -- 00:00:23.715 we mentioned earlier with Robbie's question, even the currently indicated population 00:00:23.715 -- 00:00:28.760 is way underpenetrated, and that's why we aren't very comfortable in that 20% 00:00:28.760 -- 00:00:32.919 growth. over the long-range plan. But I think, you know, to answer your questions about 00:00:32.919 -- 00:00:37.963 some of the studies that are coming up, let me talk, you know, about them first 00:00:37.963 -- 00:00:41.647 closure. So that's trial that is going to be reported on AHA. 00:00:41.647 -- 00:00:44.970 I don't think it's a particularly good read-through for CHAMP. 00:00:44.970 -- 00:00:48.993 It's a very different European population, a very different primary endpoint, a shorter 00:00:48.993 -- 00:00:54.078 follow-up. You know, we continue to think that other trials, like PROG-17 00:00:54.078 -- 00:00:59.549 and OPTION, honestly give us, you know, 00:00:59.549 -- 00:01:04.596 really confidence in what we hope that Champion will show. 00:01:04.596 -- 00:01:08.562 I think in terms of Olon AF 00:01:08.562 -- 00:01:13.068 and a trial called Ocean that will be reported out at AHA, 00:01:13.068 -- 00:01:18.816 you know, both of those, first off, if Ocean is confirmatory of Olon AF, 00:01:18.816 -- 00:01:23.923 that's great news, right, saying that low-risk patients undergoing AF ablation may no 00:01:23.923 -- 00:01:29.161 longer need stroke prevention. And I want to, you...